- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03283020
Opioid-Induced Swallowing Dysfunction - The Impact of Bolus Volume
Opioid-Induced Swallowing Dysfunction - The Impact of Bolus Volume: a Randomized, Double-Blind Study in Healthy Volunteers
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Monitored anesthesia care (MAC) is commonly applied in modern perioperative care and means that minor surgical procedures are accomplished in awake patients using local anesthesia and light sedation. MAC has many advantages compared to general anesthesia; the recovery time after anesthesia is shorter and risk for postoperative nausea is lower to mention some. However, the patient is spontaneously breathing and the airway is not protected by an endotracheal tube which potentially increases risk of pulmonary aspiration. Pulmonary aspiration, that is inhalation of stomach and/or pharyngeal contents into the lungs, is a severe anesthesia-related complication and can in worst case lead to pneumonia and even death. Intact swallowing function is crucial in avoiding aspiration and how sedatives and analgesic agents used during MAC influence swallowing function is not fully understood.
Pharyngeal function during bolus swallowing is measured by combined high resolution impedance manometry (HRIM). The HRIM catheter is inserted through the nose in such a way that sensors straddle the entire pharynx and esophagus with the distal catheter tip in the stomach. Dynamic pressure changes and flow can be detected during swallowing and data registered by HRIM are analysed using purpose-designed software, AIM analysis (automated impedance manometry analysis). AIM analysis derives pressure flow variables which describe different physiological events like bolus timing and bolus distension in the pharynx and the esophagus during swallowing. A Swallow Risk Index value, quantifying risk of deglutitive aspiration, can also be defined.
The aim of the study is to evaluate impact of different bolus volumes on remifentanil-induced swallowing dysfunction in healthy volunteers. The study will clarify underlying mechanisms (central vs. peripheral effects) of remifentanil-induced swallowing dysfunction. Furthermore, whether swallowing tasks can be done safer during sedation by altering bolus volumes will be revealed. In addition to bolus volume, different bolus viscosities will be tested. It is shown that higher bolus viscosity diminishes misdirected swallows in dysphagic patients and higher bolus viscosity may possibly counteracts the swallowing dysfunction induced by remifentanil. Moreover, if MNTX reverses the remifentanil-induced effects on swallowing, then this would suggest a dominant peripherally mediated mechanism. Our aim is also to evaluate impact of remifentanil exposure on esophageal motility and impact of methylnaltrexone alone on swallowing function.
20 healthy volunteers will be studied on two different occasions approximately one week apart. In a randomized order volunteers will receive intravenous infusion of remifentanil and an intravenous injection of MNTX on one occasion, and placebo (normal saline) infusion and an intravenous injection of MNTX on the other occasion. Blood samples are obtained for plasma concentration determination of the study drug and sedation levels are assessed during study drug exposure.
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Örebro, Suecia, 70185
- Reclutamiento
- Department of Anaesthesiology and Intensive Care, Örebro University Hospital
-
Contacto:
- Johanna Savilampi, Phd
- Correo electrónico: johanna.savilampi@regionorebrolan.se
-
Contacto:
- Per Cajander, MD
- Correo electrónico: per.cajander@regionorebrolan.se
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- ≥ 18 - ≤ 40 year old healthy volunteers from both sexes.
- Have signed and dated Informed Consent.
- Willing and able to comply with the protocol for the duration of the trial.
Exclusion Criteria:
- Anamnesis of pharyngoesophageal dysfunction.
- Known or history of gastrointestinal, severe cardiac, pulmonary or neurological disease
- Ongoing medication that may affect upper gastrointestinal tract, larynx or lower airway.
- Allergies to or history of reaction to remifentanil, fentanyl analogues or dexmedetomidine.
- Pregnancy or breast feeding
- BMI > 30
- Smoking
- Previous participation in a medicinal clinical trial during the last year where an opioid has been used or have during the last 30 days participated in any other medicinal clinical trial or in a trial where follow-up is not completed.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: RemifentanilMNTX
Volunteers are given an intravenous infusion with remifentanil, with an effect-site target concentration of 3 ng/ml via a target-controlled infusion (TCI) pump.
After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
|
Remifentanil infusion TCI 3 ng/ml, Methylnaltrexone injection 0.3 mg/kg
Otros nombres:
|
|
Comparador activo: PlaceboMNTX
Volunteers are given an intravenous infusion with saline 0,9%.
After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
|
Placebo (NaCl 0.9%) TCI infusion, Methylnaltrexone injection 0.3 mg/kg
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Pressure Flow pharyngeal variables, 10 ml vs 20 ml bolus
Periodo de tiempo: Up to 60 minutes
|
Difference in pharyngeal pressure flow variables during remifentanil exposure between bolus volumes of 10 ml and 20 ml compared to placebo.
|
Up to 60 minutes
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Pressure Flow pharyngeal variables, liquid vs semisolid bolus
Periodo de tiempo: Up to 60 minutes
|
Difference in pharyngeal pressure flow variables during remifentanil exposure between liquid and semisolid boluses compared to placebo
|
Up to 60 minutes
|
|
Pressure Flow pharyngeal variables, remifentanil before vs after methylnaltrexone
Periodo de tiempo: Up to 60 minutes
|
Difference in pharyngeal pressure flow variables during remifentanil exposure before and after methylnaltrexone administration compared to placebo.
|
Up to 60 minutes
|
|
Pressure Flow pharyngeal variables, placebo before vs after methylnaltrexone
Periodo de tiempo: Up to 60 minutes
|
Difference in pharyngeal pressure flow variables during placebo infusion before and after methylnaltrexone administration.
|
Up to 60 minutes
|
|
Pressure Flow esophageal motility variables, 10 ml vs 20 ml bolus
Periodo de tiempo: Up to 60 minutes
|
Difference in variables of esophageal motility between different bolus volumes during remifentanil exposure compared to placebo.
|
Up to 60 minutes
|
|
Pressure Flow esophageal motility variables, liquid vs semisolid bolus
Periodo de tiempo: Up to 60 minutes
|
Difference in variables of esophageal motility between liquid and semisolid boluses during remifentanil exposure compared to placebo.
|
Up to 60 minutes
|
|
Pressure Flow esophageal motility variables, remifentanil before vs after methylnaltrexone
Periodo de tiempo: Up to 60 minutes
|
Difference in variables of esophageal motility during remifentanil exposure before and after methylnaltrexone administration compared to placebo.
|
Up to 60 minutes
|
|
Pressure Flow esophageal motility variables, placebo before vs after methylnaltrexone
Periodo de tiempo: Up to 60 minutes
|
Difference in variables of esophageal motility during placebo infusion before and after methylnaltrexone administration.
|
Up to 60 minutes
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Johanna Savilampi, MD, PhD, University Hospital in Örebro
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- JS006
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .